IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

About CF » CFTR mutations » The correlation between CFTR mutations and disease severity

The correlation between CFTR mutations and disease severity

Cystic fibrosis symptoms are highly varied among individual patients, even between siblings who carry identical CFTR alleles. This variation is thought to be influenced by non-genetic factors and modifier genes:1

  • Non-genetic factors include environmental factors (e.g. air quality), level of care, nutritional status and age of onset of lung infection2
  • Modifier genes are thought to interact with CFTR mutations to influence disease severity. For example, reduced amounts of the immune protein mannose-binding lectin (MLB2) is associated with increased rates of CF-related bronchiectasis, which is in part due to earlier colonisation of Pseudomonas aeruginosa in the lung3

m1_s1_03_02_01

This diagram shows the relationship between the type of CFTR gene mutation (genotype) and CF disease severity (or phenotype). For example, certain ‘mild’ CFTR mutations may have increased risk to particular pulmonary conditions such as asthma.4 Patients with ‘severe’ CFTR mutations present with classical CF symptoms.4 This diagram, however, does not take environmental factors into consideration. [Modified from Zielenski.5]

 

What factors influence CF disease severity?

Click on the button below to find out.

References
  1. Rowntree R & Harris A. Ann Hum Genet 2003;67:471–85
  2. Cutting GR. Ann NY Acad Sci 2010;1214:57–69
  3. Chalmers JD et al. Glycobiology 2011;21:271–82
  4. Bombieri C et al. J Cyst Fibros 2011;10(Suppl 2):S86–102
  5. Zielenski J. Respiration 2000;67:117–33